ARTICLE | Company News
Gilead, Japan Tobacco deal
January 2, 2012 8:00 AM UTC
Gilead granted Japan Tobacco exclusive rights in Japan to develop and commercialize cobicistat. Cobicistat, an inhibitor of cytochrome P450 family 3 subfamily A ( CYP3A), is in Phase III testing outside of Japan as a boosting agent in HIV medicines. Details were not disclosed. ...